JP6905538B2 - Ｅｄ−７１の固体分散体および油分分散体を含む医薬組成物 - Google Patents

Ｅｄ−７１の固体分散体および油分分散体を含む医薬組成物 Download PDF

Info

Publication number
JP6905538B2
JP6905538B2 JP2018559626A JP2018559626A JP6905538B2 JP 6905538 B2 JP6905538 B2 JP 6905538B2 JP 2018559626 A JP2018559626 A JP 2018559626A JP 2018559626 A JP2018559626 A JP 2018559626A JP 6905538 B2 JP6905538 B2 JP 6905538B2
Authority
JP
Japan
Prior art keywords
oil
water
solution
soluble polymer
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018559626A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2018124260A1 (ja
Inventor
和貴 倉崎
和貴 倉崎
隆介 ▲高▼野
隆介 ▲高▼野
慶宏 松岡
慶宏 松岡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of JPWO2018124260A1 publication Critical patent/JPWO2018124260A1/ja
Priority to JP2021104906A priority Critical patent/JP7196239B2/ja
Application granted granted Critical
Publication of JP6905538B2 publication Critical patent/JP6905538B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dispersion Chemistry (AREA)
JP2018559626A 2016-12-28 2017-12-28 Ｅｄ−７１の固体分散体および油分分散体を含む医薬組成物 Active JP6905538B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021104906A JP7196239B2 (ja) 2016-12-28 2021-06-24 Ｅｄ－７１の固体分散体および油分分散体を含む医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016256379 2016-12-28
JP2016256379 2016-12-28
PCT/JP2017/047156 WO2018124260A1 (fr) 2016-12-28 2017-12-28 Composition médicinale comprenant une dispersion solide de ed-71 et une dispersion d'huile

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021104906A Division JP7196239B2 (ja) 2016-12-28 2021-06-24 Ｅｄ－７１の固体分散体および油分分散体を含む医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2018124260A1 JPWO2018124260A1 (ja) 2019-10-31
JP6905538B2 true JP6905538B2 (ja) 2021-07-21

Family

ID=62709373

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2018559626A Active JP6905538B2 (ja) 2016-12-28 2017-12-28 Ｅｄ−７１の固体分散体および油分分散体を含む医薬組成物
JP2021104906A Active JP7196239B2 (ja) 2016-12-28 2021-06-24 Ｅｄ－７１の固体分散体および油分分散体を含む医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021104906A Active JP7196239B2 (ja) 2016-12-28 2021-06-24 Ｅｄ－７１の固体分散体および油分分散体を含む医薬組成物

Country Status (5)

Country Link
JP (2) JP6905538B2 (fr)
KR (2) KR102366186B1 (fr)
CN (1) CN110121348A (fr)
TW (1) TWI784997B (fr)
WO (1) WO2018124260A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020004541A1 (ja) * 2018-06-27 2021-07-08 中外製薬株式会社 油脂中にｅｄ−７１およびそのエポキシ体を含む油分分散体を含む医薬組成物

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112770750A (zh) * 2018-07-30 2021-05-07 中外制药株式会社 乙内酰脲衍生物的固体分散体
CN110946837A (zh) * 2019-12-11 2020-04-03 正大制药（青岛）有限公司 用于治疗骨质疏松症的艾地骨化醇片及其制备方法
CN110946844A (zh) * 2019-12-11 2020-04-03 正大制药（青岛）有限公司 一种含有艾地骨化醇的复方控释制剂

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58206533A (ja) * 1982-05-27 1983-12-01 Teijin Ltd 活性型ビタミンｄ↓３誘導体組成物及びそれを活性成分とする薬剤
JPS59155309A (ja) * 1983-02-22 1984-09-04 Teijin Ltd 活性型ビタミンｄ↓３類組成物
JPS6217A (ja) * 1985-02-14 1987-01-06 Chugai Pharmaceut Co Ltd 安定な活性型ビタミンｄ３類製剤
JP2525478B2 (ja) * 1989-03-01 1996-08-21 帝人株式会社 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
JPH02240024A (ja) * 1989-03-13 1990-09-25 Ss Pharmaceut Co Ltd 活性型ビタミンｄ↓３類製剤用組成物
US7632518B2 (en) * 2002-01-15 2009-12-15 Dsm Ip Assets B.V. 25-hydroxy vitamin D3 compositions
EP1336602A1 (fr) * 2002-02-13 2003-08-20 Giovanni Scaramuzzino Prodrogues nitrées capable de libérer du monoxyde d'azote de manière controlée et sélective ainsi que leur utilisation pour la prévention et le traitement de maladies inflammatoires, ischémiques et proliferatives
US9247765B2 (en) * 2004-01-14 2016-02-02 Omniactive Health Technologies Limited Stable beadlets of lipophilic nutrients
US20070129340A1 (en) * 2004-02-06 2007-06-07 Chugai Seiyaku Kabushiki Kaisha Ed-71 preparation
WO2006075690A1 (fr) * 2005-01-14 2006-07-20 Ono Pharmaceutical Co., Ltd. Composition medicale stable
JP2007099760A (ja) * 2005-09-06 2007-04-19 Ono Pharmaceut Co Ltd 軟骨再生用医薬組成物
KR100822133B1 (ko) * 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
KR20080076382A (ko) * 2007-02-15 2008-08-20 (주)아모레퍼시픽 실로스타졸의 제어방출 제제 및 그 제조방법
JP4934840B2 (ja) * 2008-08-20 2012-05-23 石川県 脂溶性ビタミンないし脂溶性ビタミン様物質の油脂−糖質粉末素材及びその製造方法
CN102688249A (zh) 2012-05-14 2012-09-26 北京阜康仁生物制药科技有限公司 一种含有锶盐的药用组合物
WO2015119183A1 (fr) * 2014-02-05 2015-08-13 協和発酵キリン株式会社 Médicament liquide contenant de la vitamine d3 active ou un dérivé de celle-ci

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020004541A1 (ja) * 2018-06-27 2021-07-08 中外製薬株式会社 油脂中にｅｄ−７１およびそのエポキシ体を含む油分分散体を含む医薬組成物
JP2022065053A (ja) * 2018-06-27 2022-04-26 中外製薬株式会社 油脂中にｅｄ－７１およびそのエポキシ体を含む油分分散体を含む医薬組成物
JP7291138B2 (ja) 2018-06-27 2023-06-14 中外製薬株式会社 油脂中にｅｄ－７１およびそのエポキシ体を含む油分分散体を含む医薬組成物
JP7406581B2 (ja) 2018-06-27 2023-12-27 中外製薬株式会社 油脂中にｅｄ－７１およびそのエポキシ体を含む油分分散体を含む医薬組成物

Also Published As

Publication number Publication date
TWI784997B (zh) 2022-12-01
JP2021155437A (ja) 2021-10-07
KR102583517B1 (ko) 2023-09-26
CN110121348A (zh) 2019-08-13
KR102366186B1 (ko) 2022-02-21
JP7196239B2 (ja) 2022-12-26
WO2018124260A1 (fr) 2018-07-05
KR20220025177A (ko) 2022-03-03
JPWO2018124260A1 (ja) 2019-10-31
TW201834661A (zh) 2018-10-01
KR20190101981A (ko) 2019-09-02

Similar Documents

Publication Publication Date Title
JP7196239B2 (ja) Ｅｄ－７１の固体分散体および油分分散体を含む医薬組成物
KR102072546B1 (ko) 레날리도마이드의 경구용 정제 조성물
KR20070115918A (ko) 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
WO2011081199A1 (fr) Préparation à usage oral améliorée en qualité
JP2011162531A (ja) フェキソフェナジン含有フイルムコーテイング経口製剤
JP2018090601A (ja) ビロキサジンの緩和放出製剤
US20190125792A1 (en) Pharmaceutical compositions comprising ferric citrate and methods for the production thereof
RU2727721C2 (ru) Фармацевтическая композиция с замедленным высвобождением, содержащая ривастигмин
CA3190856A1 (fr) Formes posologiques solides de palbociclib
JP6328138B2 (ja) Ｎ−［５−［２−（３，５−ジメトキシフェニル）エチル］−２ｈ−ピラゾール−３−イル］−４−［（３ｒ，５ｓ）−３，５−ジメチルピペラジン−１−イル］ベンズアミドの医薬製剤
JP7406581B2 (ja) 油脂中にｅｄ－７１およびそのエポキシ体を含む油分分散体を含む医薬組成物
KR20040079325A (ko) 메트포르민 및 글리부라이드의 고형 경구용 제형 및 이의제조 방법
EP3184101A1 (fr) Composition à libération modifiée de lévodopa et de carbidopa
JP2020075874A (ja) ルビプロストン含有フィルム状医薬組成物
EP1438961B1 (fr) Composition bioéquivalente sous la forme d'une dispersion solide comprenant de l'itraconazole et un polymer hydrophile
EP1438960B2 (fr) Composition sous la forme d'une dispersion solide comprenant de l'itraconazole et un polymer hydrophilique dont la biodisponibilité est améliorée
JP4603803B2 (ja) 放出制御医薬組成物およびこれを用いる製剤
US20040086567A1 (en) Bioequivalent composition of itraconazole and a hydrophilic polymer
EP2382968A1 (fr) Répartition de la Grosseur de Particules des Granules d'Acide Fusidique

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201225

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210413

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20210423

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210513

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210521

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210610

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210625

R150 Certificate of patent or registration of utility model

Ref document number: 6905538

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150